Bone geometry, bone mineral density, and micro-architecture in patients with myelofibrosis: a cross-sectional study using DXA, HR-pQCT, and bone turnover markers

详细信息    查看全文

• 作者：Sarah Farmer ; Hanne Vestergaard ; Stinus Hansen&#8230
• 关键词：Myelofibrosis ; Bone structure ; Bone geometry ; Bone mineral density ; Osteosclerosis ; Bone turnover
• 刊名：International Journal of Hematology
• 出版年：2015
• 出版时间：July 2015
• 年：2015
• 卷：102
• 期：1
• 页码：67-75
• 全文大小：457 KB
• 参考文献：1.Swerdlow SHCE, Harris NL et al. WHO classification of tumours of the haematopoietic and lymphoid tissues. France: IARC; 2008.
  2.Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Current Hematol Malig Rep. 2009;4(1):33鈥?0.View Article
  3.Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372鈥?.PubMed
  4.Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401鈥?.View Article PubMed
  5.Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68鈥?6.View Article PubMed
  6.Tefferi A. Myelofibrosis with myeloid metaplasia. New Engl J Med. 2000;342(17):1255鈥?5.View Article PubMed
  7.Mellibovsky L, Marinoso ML, Cervantes F, Besses C, Nacher M, Nogues X, et al. Relationship among densitometry, bone histomorphometry, and histologic stage in idiopathic myelofibrosis. Bone. 2004;34(2):330鈥?.View Article PubMed
  8.Diamond T, Smith A, Schnier R, Manoharan A. Syndrome of myelofibrosis and osteosclerosis: a series of case reports and review of the literature. Bone. 2002;30(3):498鈥?01.View Article PubMed
  9.Poulsen LW, Melsen F, Bendix K. A histomorphometric study of haematological disorders with respect to marrow fibrosis and osteosclerosis. APMIS Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 1998;106(4):495鈥?.View Article PubMed
  10.Guermazi A, de Kerviler E, Cazals-Hatem D, Zagdanski AM, Frija J. Imaging findings in patients with myelofibrosis. Eur Radiol. 1999;9(7):1366鈥?5.View Article PubMed
  11.Farmer S, Horvath-Puho E, Vestergaard H, Hermann AP, Frederiksen H. Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study. Br J Haematol. 2013;163(5):603鈥?0.View Article PubMed
  12.Consensus development conference. diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94(6):646鈥?0.View Article
  13.Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254鈥?.PubMed Central View Article PubMed
  14.Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res Off J Am Soc Bone Miner Res. 2003;18(11):1947鈥?4.View Article
  15.Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34(1):195鈥?02.View Article PubMed
  16.Boutroy S, Bouxsein ML, Munoz F, Delmas PD. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2005;90(12):6508鈥?5.View Article PubMed
  17.Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391鈥?20 (A Journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA).View Article PubMed
  18.Campbell PJ, Green AR. The myeloproliferative disorders. New Engl J Med. 2006;355(23):2452鈥?6.View Article PubMed
  19.Schmidt M, Pedersen L, Sorensen HT. The danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541鈥?.View Article PubMed
  20.Hansen S, Shanbhogue V, Folkestad L, Nielsen MM, Brixen K. Bone microarchitecture and estimated strength in 499 adult danish women and men: a cross-sectional population-based high-resolution peripheral quantitative computed tomographic study on peak bone structure. Calcified tissue international. 2013;94:269.View Article PubMed
  21.Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature Rev Cancer. 2007;7(9):673鈥?3.View Article
  22.Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(4):392鈥?.View Article
  23.Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703鈥?.View Article PubMed
  24.Burghardt AJ, Kazakia GJ, Ramachandran S, Link TM, Majumdar S. Age- and gender-related differences in the geometric properties and biomechanical significance of intracortical porosity in the distal radius and tibia. J Bone Miner Res Off J Am Soc Bone Miner Res. 2010;25(5):983鈥?3.
  25.Nishiyama KK, Macdonald HM, Buie HR, Hanley DA, Boyd SK. Postmenopausal women with osteopenia have higher cortical porosity and thinner cortices at the distal radius and tibia than women with normal aBMD: an in vivo HR-pQCT study. J Bone Miner Res Off J Am Soc Bone Miner Res. 2010;25(4):882鈥?0.
  26.Pistoia W, van Rietbergen B, Lochmuller EM, Lill CA, Eckstein F, Ruegsegger P. Image-based micro-finite-element modeling for improved distal radius strength diagnosis: moving from bench to bedside. J Clin Densitom Off J Int Soc Clin Densitom. 2004;7(2):153鈥?0.View Article
  27.Macneil JA, Boyd SK. Bone strength at the distal radius can be estimated from high-resolution peripheral quantitative computed tomography and the finite element method. Bone. 2008;42(6):1203鈥?3.View Article PubMed
  28.Pialat JB, Burghardt AJ, Sode M, Link TM, Majumdar S. Visual grading of motion induced image degradation in high resolution peripheral computed tomography: impact of image quality on measures of bone density and micro-architecture. Bone. 2012;50(1):111鈥?.View Article PubMed
  29.Hansen S, Hauge EM, Beck Jensen JE, Brixen K. Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT. J Bone Miner Res Off J Am Soc Bone Miner Res. 2013;28(4):736鈥?5.View Article
  30.Orum O, Hansen M, Jensen CH, Sorensen HA, Jensen LB, Horslev-Petersen K, et al. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone. 1996;19(2):157鈥?3.View Article PubMed
  31.Seung H, Medige J, Ziv I. Combined models of ultrasound velocity and attenuation for predicting trabecular bone strength and mineral density. Clin Biomech. 1996;11(6):348鈥?3.View Article
  32.Merry GM, Aronowitz PB. Myelofibrosis with massive hepatosplenomegaly and osteolytic bone lesions. J Hosp Med Off Publ Soc Hosp Med. 2010;5(3):E27鈥?.View Article
  33.Assous N, Foltz V, Fautrel B, Rozenberg S, Etchepare F, Bourgeois P. Bone involvement in myelofibrosis: effectiveness of bisphosphonates. Joint Bone Spine Revue du Rhumatisme. 2005;72(6):591鈥?.View Article
  34.Blake GM, Fogelman I. An update on dual-energy X-ray absorptiometry. Semin Nucl Med. 2010;40(1):62鈥?3.View Article PubMed
  35.Gregson CL, Steel SA, O鈥橰ourke KP, Allan K, Ayuk J, Bhalla A, et al. Sink or swim: an evaluation of the clinical characteristics of individuals with high bone mass. Osteoporos Int. 2012;23(2):643鈥?4 (A Journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA).PubMed Central View Article PubMed
  36.Gregson CL, Hardcastle SA, Cooper C, Tobias JH. Friend or foe: high bone mineral density on routine bone density scanning, a review of causes and management. Rheumatology. 2013;52(6):968鈥?5.PubMed Central View Article PubMed
  37.Guggenbuhl P, Grosbois B, Chales G. Gaucher disease. Joint Bone Spine Revue du Rhumatisme. 2008;75(2):116鈥?4.View Article
  38.Rossini M, Zanotti R, Bonadonna P, Artuso A, Caruso B, Schena D, et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone. 2011;49(4):880鈥?.View Article PubMed
  39.Johansson C, Roupe G, Lindstedt G, Mellstrom D. Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing. 1996;25(1):1鈥?.View Article PubMed
  40.Barete S, Assous N, de Gennes C, Grandpeix C, Feger F, Palmerini F, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Annals Rheum Dis. 2010;69(10):1838鈥?1.View Article
  41.van der Veer E, van der Goot W, de Monchy JG, Kluin-Nelemans HC, van Doormaal JJ. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy. 2012;67(3):431鈥?.View Article PubMed
  42.Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol. 2002;128(4):344鈥?0.View Article PubMed
  43.Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer. Blood. 2012;119(14):3219鈥?5.View Article PubMed
  44.Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol. 2005;130(5):709鈥?5.View Article PubMed
  45.Pardanani A. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011;86(4):362鈥?1.View Article PubMed
  46.Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T, et al. International osteoporosis foundation and international federation of clinical chemistry and laboratory medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med CCLM/FESCC. 2011;49(8):1271鈥?.
  47.Barosi G, Costa A, Liberato LN, Polino G, Spriano P, Magrini U. Serum procollagen-III-peptide level correlates with disease activity in myelofibrosis with myeloid metaplasia. Br J Haematol. 1989;72(1):16鈥?0.View Article PubMed
  48.Jensen MK, Riisbro R, Holten-Andersen MN, Brown Pde N, Junker P, Brunner N, et al. Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism. Eur J Haematol. 2003;71(4):276鈥?2.View Article PubMed
  49.Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139(3):351鈥?2.View Article PubMed
  50.Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia. 2013;27(10):1953鈥?.View Article PubMed
  51.Liu XS, Cohen A, Shane E, Yin PT, Stein EM, Rogers H, et al. Bone density, geometry, microstructure, and stiffness: relationships between peripheral and central skeletal sites assessed by DXA, HR-pQCT, and cQCT in premenopausal women. J Bone Miner Res Off J Am Soc Bone Miner Res. 2010;25(10):2229鈥?8.View Article
  52.Boutroy S, Van Rietbergen B, Sornay-Rendu E, Munoz F, Bouxsein ML, Delmas PD. Finite element analysis based on in vivo HR-pQCT images of the distal radius is associated with wrist fracture in postmenopausal women. J Bone Miner Res Off J Am Soc Bone Miner Res. 2008;23(3):392鈥?.View Article
  53. Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelfibrosis (Mf), essential thrombocythemia (Et), and polycythemia vera (Pv) in the european union (Eu). Eur J Haematol. 2013.
  54. Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leukemia Lymphoma. 2013.
  55.Cervantes F, Dupriez B, Passamonti F, Vannucchi AM, Morra E, Reilly JT, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(24):2981鈥?.View Article
  
• 作者单位：Sarah Farmer (1)
  Hanne Vestergaard (1)
  Stinus Hansen (2)
  Vikram Vinod Shanbhoque (2)
  Claudia Irene Stahlberg (3)
  Anne Pernille Hermann (2)
  Henrik Frederiksen (1) (4)
  
  1. Department of Haematology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark
  2. Department of Endocrinology, Odense University Hospital, Odense, Denmark
  3. Department of Pathology, Section of Haemapathology, Odense University Hospital, Odense, Denmark
  4. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
  
• 刊物主题：Hematology; Oncology;
• 出版者：Springer Japan
• ISSN：1865-3774

文摘

Primary myelofibrosis (MF) is a severe chronic myeloproliferative neoplasm, progressing towards a terminal stage with insufficient haematopoiesis and osteosclerotic manifestations. Whilst densitometry studies have showed MF patients to have elevated bone mineral density, data on bone geometry and micro-structure assessed with non-invasive methods are lacking. We measured areal bone mineral density (aBMD) using dual-energy X-ray absorptiometry (DXA). Bone geometry, volumetric BMD, and micro-architecture were measured using high-resolution peripheral quantitative computed tomography (HR-pQCT). We compared the structural parameters of bones by comparing 18 patients with MF and healthy controls matched for age, sex, and height. Blood was analysed for biochemical markers of bone turnover in patients with MF. There were no significant differences in measurements of bone geometry, volumetric bone mineral density, and micro-structure between MF patients and matched controls. Estimated bone stiffness and bone strength were similar between MF patients and controls. The level of pro-collagen type 1 N-terminal pro-peptide (P1NP) was significantly increased in MF, which may indicate extensive collagen synthesis, one of the major diagnostic criteria in MF. We conclude that bone mineral density, geometry, and micro-architecture in this cohort of MF patients are comparable with those in healthy individuals.